Cargando…
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection
Hepatitis C virus (HCV) infection is a major cause of end-stage liver disease, including decompensated cirrhosis and hepatocellular carcinoma. Over 95% of patients with HCV infection have achieved sustained virologic response at 12 weeks under the treatment of several pan-genotypic regimens approved...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
XIA & HE Publishing Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868694/ https://www.ncbi.nlm.nih.gov/pubmed/33604263 http://dx.doi.org/10.14218/JCTH.2020.00078 |